1.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
|
|
2.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 1 to 30 Sponsor: Other Protocol IDs: OHSU-5056, SOL-08131-L, NCT00983398
|
|
4.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
|
|
6.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
|
|
7.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: Pro00018020, NCT01326104
|
|
8.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 12 months to 30 years Sponsor: Pharmaceutical / Industry Protocol IDs: NMTRC 004, NCT01483820
|
|
9.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Pharmaceutical / Industry Protocol IDs: V0706, NCT00601003
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: NCI Protocol IDs: NCI-2011-02605, ACNS0821, U10CA098543, COG-ACNS0821, NCT01217437
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02546, PBTC-032, U01CA081457, NCT01239316
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 12 to 21 Sponsor: NCI, Other Protocol IDs: PBTC-036, NCI-2013-00482, U01CA081457, NCT01836549
|
|
16.
|
Phase: Phase I Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
|
|
17.
|
Phase: Phase I Type: Treatment Status: Active Age: 2 to 25 Sponsor: NCI, Other Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023
|
|
18.
|
Phase: Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245
|
|
19.
|
Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: RADBEV, NCT00756340
|
|
20.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2009-01180, PBTC-025, U01CA081457, CDR0000631677, NCT00822458
|
|
21.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 months to 23 years Sponsor: Other Protocol IDs: ACH-CNS-001, NCT00876993
|
|
22.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: 110047, 11-C-0047, NCT01259479
|
|
23.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: SorIrin1576, NCT01518413
|
|
24.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: 163588-1, NCT01682746
|
|
25.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 1 to 21 Sponsor: Pharmaceutical / Industry Protocol IDs: 14492, I4J-MC-HHBD, NCT01697514
|